B
B

BectonDickinson

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Bd Receives FDA 510(K) Clearance For First-Of-Its-Kind High-Throughput Diagnostic Test For Infectious Vaginitis

BRIEF-Bd Receives FDA 510(K) Clearance For First-Of-Its-Kind High-Throughput Diagnostic Test For Infectious Vaginitis March 16 (Reuters) - Becton Dickinson and Co BDX.N : BD RECEIVES FDA 510(K) CLEARANCE FOR FIRST-OF-ITS-KIND HIGH-THROUGHPUT DIAGNOSTIC TEST FOR INFECTIOUS VAGINITIS Source text for Eikon: ID:nPnbpdtrPa Further company coverage: BDX.
B

Becton Dickinson's Hpv Assay Receives FDA Approval

BRIEF-Becton Dickinson's Hpv Assay Receives FDA Approval Feb 21 (Reuters) - Becton Dickinson and Co BDX.N : BD ONCLARITY™ HPV ASSAY RECEIVES FDA APPROVAL FOR USE WITH BOTH BD SUREPATH™ LIQUID-BASED PAP TEST AND HOLOGIC THINPREP® PAP TEST Source text for Eikon: ID:nPn2Yy08ja Further company coverage: BDX.N
B

Bard convinces U.S. appeals court to revive medical-injection device patents

Bard convinces U.S. appeals court to revive medical-injection device patents Bard's infringement case against MedComp over injection 'access ports' reinstated MedComp also gets chance to save countersuit against Bard By Blake Brittain (Reuters) - Becton Dickinson's BDX.N C.R. Bard Inc on Friday won a ruling from a U.S. appeals court reinstating three patents related to its PowerPort devices for delivering repeated medical injections.
B

BD Receives FDA Emergency Use Authorization For Covid-19, Influenza A/B, Rsv Combination Test

BRIEF-BD Receives FDA Emergency Use Authorization For Covid-19, Influenza A/B, Rsv Combination Test Feb 8 (Reuters) - Becton Dickinson and Co BDX.N : BD RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR COVID-19, INFLUENZA A/B, RSV COMBINATION TEST Source text for Eikon: ID:nPnbY32yfa Further company coverage: BDX.N
B

Becton Dickinson Euro Finance S.À R.L. Files For Offering Of Euro-Denominated Notes Guaranteed By Becton, Dickinson And Company, Size Not Disclosed

BRIEF-Becton Dickinson Euro Finance S.À R.L. Files For Offering Of Euro-Denominated Notes Guaranteed By Becton, Dickinson And Company, Size Not Disclosed Feb 6 (Reuters) - Becton Dickinson and Co BDX.N : BECTON DICKINSON EURO FINANCE S.À R.L. FILES FOR OFFERING OF EURO-DENOMINATED NOTES GUARANTEED BY BECTON, DICKINSON AND COMPANY, SIZE NOT DISCLO
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.